Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight

CendifensineAsimadolinePositive

AI Analysis

Summary

Market analysis report projects growth in the vasomotor symptoms market through 2036, driven by improved diagnosis, treatment advancements, aging demographics, and emerging therapies including Cendifensine and Asimadoline.

Importance:2/10

Sentiment:

0.40

vasomotor symptomsmarket analysishormonal therapynon-hormonal therapyemerging therapies

Read the original article

Published by PR Newswire Pharma on September 30, 2026 2:31 PM

Read Original